By joining forces, IDT will pair its nearly 40-year legacy of quality and service, as well as its global presence, with ...

Integrated DNA Technologies collaborates with Ansa Biotechnologies to expand capabilities to IDT’s synthetic biology portfolio: Sunnyvale Saturday, January 17, 2026, 14:00 Hrs [ ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...

There’s an old saying about a dollar waiting on a dime. In other words, a monumental endeavor may become stuck at some point if a key preliminary element remains unavailable. The saying could be ...

Despite these advances, the synthesis of DNA nanostructures has remained a largely manual and time-consuming process. Traditional approaches often require the precise mixing of hundreds of unique DNA ...

From synthetic biology and gene therapy to data storage and biofuel production, the demand for synthetic DNA is rising. (1) Chemicals remove the 5’-hydroxyl protecting group. The nucleosides are rich ...

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B round of financing that will be used to expand the company’s DNA synthesis production capacity in the U.S. The San ...